Fulgent Genetics Closes Dual Pathology Deal

Fulgent Genetics ( NASDAQ: FLGT) has finalized its acquisition of two specialty pathology laboratories — Bako Diagnostics and StrataDx, for approximately $56.9 million in cash, subject to post-closing adjustments. The transaction, first announced on December 22, 2025, closes a chapter that began as a deliberate push into higher-value diagnostic segments and signals where FLGT sees its next phase of growth.

What’s Been Added to the Platform

The two acquisitions are complementary rather than redundant, each covering distinct clinical territory.

Bako Diagnostics extends Fulgent’s reach into anatomic pathology, molecular diagnostics, and specialized neuropathy testing — a suite that broadens the company’s menu well beyond its genomics core and adds a national client base with an established sales infrastructure.

StrataDx, based in Lexington, Massachusetts, is a recognized leader in dermatopathology, with board-certified specialists covering skin conditions ranging from melanocytic lesions to lymphomas, as well as oral pathology services. For Fulgent, this fills a meaningful gap in its testing portfolio and opens a direct channel into the dermatology market.

Scale, Sales, and Geographic Reach

Beyond the testing capabilities themselves, the deals bring operational scale that matters to investors. The integration of Bako alone is expected to meaningfully expand Fulgent’s pathology-focused sales team, improving both market penetration and proximity to referring physicians. Additional laboratory facilities in key regions further strengthen the company’s national footprint — an asset that becomes more valuable as Fulgent pursues volume-driven revenue growth.

Technology as the Multiplier

Fulgent isn’t acquiring these labs to run them as-is. The company intends to layer in its digital pathology and artificial intelligence capabilities, targeting improvements in turnaround times, diagnostic precision, and overall lab efficiency. This technology integration is central to the investment thesis: the acquired businesses provide the patient volume and clinical infrastructure, while Fulgent’s proprietary tools provide the margin-expanding edge.

Strategic Fit Within the Broader FLGT Story

Fulgent has been deliberately constructing a platform that spans genetic testing, anatomic pathology, and therapeutic development — the last of which centers on a nanoencapsulation-based cancer drug pipeline. The Bako and StrataDx acquisitions accelerate the diagnostics side of that equation, adding recurring revenue streams and a more diversified payer mix. For investors tracking the company’s evolution from a genomics testing shop into a full-spectrum precision medicine provider, this deal moves the needle.

Bottom Line for Investors

At $56.9 million in cash, Fulgent is making a focused, strategically coherent bet on pathology services as a growth driver. The combination of expanded test offerings, a larger sales force, additional lab infrastructure, and planned AI integration positions FLGT to compete more aggressively in a diagnostics market that increasingly rewards scale and technological differentiation. Investors should watch post-integration revenue contribution from these assets as a near-term indicator of execution quality.